EGFR and non-small cell lung carcinoma: In this light, managing a patient with EGFR mutant NSCLC experiencing a relapse shortly after completing adjuvant osimertinib therapy can pose challenges, due to the insufficient evidence demonstrating the superiority of initiating first-line polychemotherapy instead of rechallenging.